For research use only. Not for therapeutic Use.
Fletikumab (NNC0109-0012) is a monoclonal antibody targeting to IL-20. Fletikumab can be used for inflammation research, such as rheumatoid arthritis[1].
Fletikumab blocks IL-20 binding IL-20 receptor, acts potential function of inflammation inhibition[1].
IL-20 is a member of IL-10 family, which includes IL-10, IL-19, IL-22, IL-24, IL-26, IL-28, and IL-29. IL-20 acts on renal cells and contributes to inflammation, fibrosis, and apoptosis through its receptors IL-20R1, IL-20R2, and IL-22R1[2].
| Catalog Number | I042730 |
| CAS Number | 1357158-22-5 |
| Purity | ≥95% |
| Reference | [1]. Kragstrup TW, et al. The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis. Front Immunol. 2018 Sep 25;9:2226. [2]. Tian-Yu Lin, et al. IL-20 in Acute Kidney Injury: Role in Pathogenesis and Potential as a Therapeutic Target. Int. J. Mol. Sci. 2020, 21(3), 1009. |
